NPM1 and acute myeloid leukemia: In a phase 1b/2 trial (NCT02343939), entospletinib, a selective oral inhibitor of the spleen tyrosine kinase (SYK) which is constitutively activated in AML promoting survival and proliferation [103], when combined with chemotherapy, was more active in patients with HOXA9/MEIS1 signature (as in NPM1-mutated AML) than in the whole patient population [104] (Fig. 2).